NIP
ITCI

Nicholas Investment Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Nicholas Investment Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-176,870
Closed -$14.8M – 242
2024
Q4 		$14.8M Buy
176,870
+22,072
+14% +$1.81M 1.3% 10
2024
Q3 		$11.3M Buy
154,798
+3,389
+2% +$255K 1.04% 22
2024
Q2 		$10.4M Buy
151,409
+80,038
+112% +$5.55M 1.08% 22
2024
Q1 		$4.94M Buy
71,371
+21,127
+42% +$1.45M 0.51% 71
2023
Q4 		$3.6M Sell
50,244
-285,310
-85% -$16.4M 0.42% 90
2023
Q3 		$17.5M Sell
335,554
-163,949
-33% -$9.55M 1.31% 24
2023
Q2 		$31.6M Buy
+499,503
New +$31.1M 2.16% 10
2023
Q1 		– Sell
-413,507
Closed -$21.9M – 218
2022
Q4 		$21.9M Buy
413,507
+22,829
+6% +$1.14M 1.92% 7
2022
Q3 		$18.2M Sell
390,678
-43,281
-10% -$2.26M 1.69% 9
2022
Q2 		$24.8M Sell
433,959
-128,414
-23% -$7.28M 2.34% 2
2022
Q1 		$34.4M Sell
562,373
-90,513
-14% -$4.7M 2.45% 1
2021
Q4 		$34.2M Buy
652,886
+39,674
+6% +$1.67M 2.16% 1
2021
Q3 		$22.9M Buy
613,212
+14,951
+2% +$520K 1.67% 7
2021
Q2 		$24.4M Buy
598,261
+43,716
+8% +$1.62M 1.53% 8
2021
Q1 		$18.8M Buy
554,545
+164,256
+42% +$5.7M 1.31% 24
2020
Q4 		$12.4M Sell
390,289
-67,431
-15% -$1.77M 0.96% 33
2020
Q3 		$11.7M Buy
+457,720
New +$10.4M 1.27% 25
2016
Q4 		– Sell
-43,181
Closed -$658K – 346
2016
Q3 		$658K Sell
43,181
-3,219
-7% -$130K 0.04% 292
2016
Q2 		$1.8M Buy
+46,400
New +$1.67M 0.12% 264
2015
Q3 		– Sell
-8,130
Closed -$260K – 330
2015
Q2 		$260K Buy
+8,130
New +$206K 0.02% 302

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Nicholas Investment Partners's ITCI Position: Q1 2025 in Review

Nicholas Investment Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 176,870 shares — an estimated $14.8M sold.

Nicholas Investment Partners first reported a position in ITCI in Q2 2015 and held it in 20 quarters. The position peaked at $34.4M in Q1 2022. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Nicholas Investment Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Nicholas Investment Partners sold 176,870 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $14.8M.
  • Nicholas Investment Partners first reported a position in Intra-Cellular Therapies Inc. in Q2 2015 and held it in 20 quarters.
  • Nicholas Investment Partners's Intra-Cellular Therapies Inc. position peaked at $34.4M in Q1 2022.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Nicholas Investment Partners's 13F filing for Q1 2025, filed 15 May 2025.